Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. (Q54493139)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

main subject

chronic myeloid leukemia

0 references

dactolisib

1 reference

ChEBI release 2020-05-28

1 reference

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Sebastian Halbach

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Patrick Auberger

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Tilman Brummer

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

12

H L Pahl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

8

J M Penninger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

F U Wöhrle

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

K Aumann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

S Schwemmers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

S Braun

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

D Schramek

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

S Laßmann

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M Werner

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

C F Waller

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

R Zeiser

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

3 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

118-129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2012.222

9 February 2020

exact match

0 references

cites work

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Regulation of the c-Abl and Bcr-Abl tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Critical role for Gab2 in transformation by BCR/ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Charting the molecular network of the drug target Bcr-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Function, regulation and pathological roles of the Gab/DOS docking proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Distinct binding modes of two epitopes in Gab2 that interact with the SH3C domain of Grb2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Essential role for Gab2 in the allergic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Gab2 promotes hematopoietic stem cell maintenance and self-renewal synergistically with STAT5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Abnormal hematopoiesis in Gab2 mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

PKB-mediated negative feedback tightly regulates mitogenic signalling via Gab2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Gene expression changes associated with progression and response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

A novel MCF-10A line allowing conditional oncogene expression in 3D culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Gab2 and Src co-operate in human mammary epithelial cells to promote growth factor independence and disruption of acinar morphogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

inferred from DOI database lookup

7 January 2021

based on heuristic

Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

inferred from DOI database lookup

7 January 2021

based on heuristic

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.222

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2012.222

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22858987%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference